4
Changes in Ownership
Xilio Therapeutics, Inc. Filed Acc 0001193125-26-002517
Chief Financial Officer sold 7,030 shares at $0.64 ($4,522)
- Chief Financial Officer acquired 19,375 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Frankenfield Christopher James · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-01 | Exercise or conversion : show line 1 in the form 10b5-1 | +19,375 | 31,796 | D | ||
| 2026-01-02 | Sale : show line 2 in the form 10b5-1 | −7,030 | $0.64 | $4,522 | 24,766 | D |
| Open-market sales · 7,030 sh · avg $0.64 · $4,522 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-12-31 | Grant or award : show line 3 in the form 10b5-1 Stock Option (right to buy) | +668,789 | 668,789 | D |
| 2026-01-01 | Exercise or conversion : show line 4 in the form 10b5-1 Restricted Stock Units | −19,375 | 38,750 | D |
Loading xslF345X05/ownership.xml…